Přihlásit se Zaregistrujte se zdarma

EBITDA margin společnosti Kazia Therapeutics

Jaká je hodnota metriky EBITDA margin společnosti Kazia Therapeutics?

Hodnota metriky EBITDA margin společnosti Kazia Therapeutics Limited je -229,127.60%

Jaká je definice metriky EBITDA margin?



EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.

ttm (trailing twelve months)

EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.

EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.

EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.

EBITDA margin společností v sektoru Health Care sektor na ASX ve srovnání se společností Kazia Therapeutics

Čemu se věnuje společnost Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Firmy s metrikou ebitda margin podobnou společnosti Kazia Therapeutics



  • Hodnota metriky EBITDA margin společnosti Summit Therapeutics Inc je -263,438.64%
  • Hodnota metriky EBITDA margin společnosti 3D Oil je -242,673.23%
  • Hodnota metriky EBITDA margin společnosti Evrim Resources je -240,047.15%
  • Hodnota metriky EBITDA margin společnosti DeepMarkit je -239,530.43%
  • Hodnota metriky EBITDA margin společnosti ICS Global je -235,628.81%
  • Hodnota metriky EBITDA margin společnosti Titan Pharmaceuticals, (de) je -230,150.00%
  • Hodnota metriky EBITDA margin společnosti Kazia Therapeutics je -229,127.60%
  • Hodnota metriky EBITDA margin společnosti Aurum Resources Ltd je -226,933.33%
  • Hodnota metriky EBITDA margin společnosti Mayur Resources Ltd je -225,062.55%
  • Hodnota metriky EBITDA margin společnosti Tocagen je -224,696.30%
  • Hodnota metriky EBITDA margin společnosti Hannans je -217,102.01%
  • Hodnota metriky EBITDA margin společnosti Laramide Resources je -215,666.29%
  • Hodnota metriky EBITDA margin společnosti Indosolar je -213,170.97%